468
Participants
Start Date
December 5, 2025
Primary Completion Date
April 13, 2035
Study Completion Date
May 31, 2037
Vorasidenib
Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles
Vorasidenib Placebo
Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles
Medical University of Innsbruck, Innsbruck
Kepler University Hospital - Neuromed campus, Linz
Medical University of Vienna, Vienna
Universitair Ziekenhuis Brussel, Brussels
Ghent University Hospital, Ghent
U.Z. Leuven - Campus Gasthuisberg, Leuven
Masaryk Memorial Cancer Institute, Brno
Universitary hospital Bordeaux France, Bordeaux
CHU Lyon - Hopital neurologique Pierre Wertheimer, Lyon
Marseille APHM, Marseille
Assistance Publique Hopitaux de Paris APHP - Sorbonne, Paris
Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse
Universitaskliniken Bonn, Bonn
University Hospital Frankfurt -Senckenberg Institute of Neurooncology, Frankfurt
NNeurology department heidelberg, Heidelberg
Mannheim University Hospital, Mannheim
Universitaetsklinikum Regensburg, Regensburg
Bellaria Hospital, IRCCS Istituto delle Scienze Neurologiche - AUSL di Bologna, Bologna
Veneto Institute of Oncology, Padua
Sapienza University, Roma
AOU Citta della Salute e della Scienza di Torino, Torino
Amsterdam UMC location VUMC, Amsterdam
Academisch Ziekenhuis Maastricht, Maastricht
Erasmus MC, Rotterdam
Hospital de Sant Pau i La Santa Creu, Barcelona
Vall de Hebron Hospital, Barcelona
Hospital Universitario 12 de Octubre, Madrid
University Hospital Basel, Basel
University Hospital Zurich, Zurich
Queen Elizabeth Hospital Birmingham, Birmingham
The Christie NHS Foundation Trust, Manchester
Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
Royal Marsden Hospital, Surrey Quays
Canadian Cancer Trials Group
NETWORK
Cooperative Trials Group for Neuro-Oncology (COGNO)
UNKNOWN
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK